Form 4 for TPST Tempest Therapeutics, Inc.
Accepted 2026-06-23 16:56:17 ET · period of report 2026-03-24 · accession 0001193125-26-279703 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-06-23 16:56 | 2026-03-24 | TPST | Angel Matthew | CEO, Pres, Dir, 10% | P - Purchase | $2.16 | +231.5K | 231.5K | New | +$500.0K |
| DMI | 2026-06-23 16:56 | 2026-03-24 | TPST | Angel Matthew | CEO, Pres, Dir, 10% | P - Purchase | — | +463.0K | 231.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-24 | P | A | 231,482 | $2.16 | 231,482 | I By Factor Bioscience Inc. | — | — | (F2) The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. (F1) On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. (F3) The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |
| 2 | Derivative | Series A Warrant (right to buy) | 2026-03-24 | P | A | 231,482 | — | 231,482 | I By Factor Bioscience Inc. | $2.16 · — to — | 231,482 Common Stock | (F1) On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. (F2) The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. (F4) The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval. (F4) The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval. (F3) The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |
| 3 | Derivative | Series B Warrant (right to buy) | 2026-03-24 | P | A | 231,482 | — | 231,482 | I By Factor Bioscience Inc. | $2.16 · — to — | 231,482 Common Stock | (F1) On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026. (F2) The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16. (F5) The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval. (F5) The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval. (F3) The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor. |